916159-99-4Relevant academic research and scientific papers
Identification of an orally bioavailable, potent, and selective inhibitor of GlyT1
Blackaby, Wesley P.,Lewis, Richard T.,Thomson, Joanne L.,Jennings, Andrew S. R.,Goodacre, Simon C.,Street, Leslie J.,MacLeod, Angus M.,Pike, Andrew,Wood, Suzanne,Thomas, Steve,Brown, Terry A.,Smith, Alison,Pillai, Gopalan,Almond, Sarah,Guscott, Martin R.,Burns, H. Donald,Eng, Waisi,Ryan, Christine,Cook, Jacquelynn,Hamill, Terence G.
scheme or table, p. 350 - 354 (2010/11/18)
Amalgamation of the structure-activity relationship of two series of GlyT1 inhibitors developed at Merck led to the discovery of a clinical candidate, compound 16 (DCCCyB), which demonstrated excellent in vivo occupancy of GlyT1 transporters in rhesus mon
Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia
-
Page/Page column 17, (2008/06/13)
The present invention provides compounds of formula I: wherein R1 is an alkyl, phenyl, heterocyclyl, cycloalkyl, alkoxy, ester, amino or amide group; R2 is a phenyl, heterocyclyl, alkyl, cycloalkyl or cycloalkylalkyl group; R3
